Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADENO-beta
2024-518095-31-00Phase 3Authorised
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in adenoviral infection and adenovirus respiratory tract infection comparing Betamethasone (Bentelan) with Placebo (2 arms). Primary endpoint: Persistent resolution of fever at 18–24 hours. Planned start Oct 2024; status: authorised.
02
Drugs
betamethasone
03
Conditions
adenoviral infectionadenovirus respiratory tract infection
Beyond the preview
Go deeper on 2024-518095-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518095-31-00.